A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
Public ClinicalTrials.gov record NCT06206837. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH PF-07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat. The study is seeking for participants who have breast cancer that: * is hard to treat (advanced) and may have spread to other organs (metastatic). * is sensitive to hormonal therapy (it is called estrogen receptor positive). * is no longer responding to treatments taken before starting this study. All the participants will receive vepdegestrant and PF-07220060. Both medicines will be taken by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicines are safe and effective. Participants will continue to take vepdegestrant and PF-07220060 until: * their cancer is no longer responding, or * side effects become too severe. They will have visits at the study clinic about every 4 weeks.
Study identification
- NCT ID
- NCT06206837
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 71 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 19, 2024 (Actual)
- Primary completion
- Sep 5, 2025 (Actual)
- Completion
- May 25, 2027 (Estimated)
- Last update posted
- Sep 30, 2026
2024 – 2027
United States locations
- U.S. sites
- 34
- U.S. states
- 9
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology | Fayetteville | Arkansas | 72703 | — |
| Highlands Oncology | Rogers | Arkansas | 72758 | — |
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| Hoag Health Center Irvine | Irvine | California | 92618 | — |
| Hoag Hospital Irvine | Irvine | California | 92618 | — |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | — |
| Clinical and Translational Research Unit (CTRU) | Palo Alto | California | 94304 | — |
| Stanford Cancer Center | Palo Alto | California | 94304 | — |
| Stanford Cancer Institute - Clinical Trials Office | Palo Alto | California | 94304 | — |
| UCSF Medical Center at Mission Bay | San Francisco | California | 94158 | — |
| UCHealth Poudre Valley Hospital | Fort Collins | Colorado | 80524 | — |
| UCHealth Harmony | Fort Collins | Colorado | 80528 | — |
| UCHealth Greeley Hospital | Greeley | Colorado | 80634 | — |
| UCHealth - Medical Center of the Rockies | Loveland | Colorado | 80538 | — |
| Smilow Cancer Hospital - Yale New Haven Health | New Haven | Connecticut | 06510 | — |
| Yale - New Haven Hospital - Yale Cancer Center | New Haven | Connecticut | 06510 | — |
| Smilow Cancer Hospital Phase 1 Unit | New Haven | Connecticut | 06511 | — |
| Smilow Cancer Hospital - Trumbull | Trumbull | Connecticut | 06611 | — |
| START Midwest | Grand Rapids | Michigan | 49546 | — |
| MSK Basking Ridge | Basking Ridge | New Jersey | 07920 | — |
| MSK Monmouth | Middletown | New Jersey | 07748 | — |
| MSK Bergen | Montvale | New Jersey | 07645 | — |
| MSK Commack | Commack | New York | 11725 | — |
| MSK Westchester | Harrison | New York | 10604 | — |
| Rockefeller Outpatient Pavilion (53rd Street) | New York | New York | 10022 | — |
| Evelyn H. Lauder Breast and Imaging Center (BAIC). | New York | New York | 10065 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| MSK Nassau | Uniondale | New York | 11553 | — |
| START San Antonio | San Antonio | Texas | 78229 | — |
| University of Utah, Farmington Health Center | Farmington | Utah | 84025 | — |
| University of Utah, Sugar House Health Center | Salt Lake City | Utah | 84106 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| South Jordan Health Center - University of Utah | South Jordan | Utah | 84106 | — |
| START Mountain Region | West Valley City | Utah | 84119 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06206837, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 30, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06206837 live on ClinicalTrials.gov.